Effects of Isolated LBBB on Maximal Functional Capacity

Left Bundle-Branch Block Clinical Trial

Official title:

Effects of Isolated Left Bundle Branch Block on Maximal Functional Capacity

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05643404
• Other study ID #: 2021/061
• Status: Recruiting
• Start date: December 22, 2022
• Est. completion date: December 31, 2024

Study information

• Verified date: September 2023
• Source: Fundación para la Investigación del Hospital Clínico de Valencia
• Contact: Marta Peiró, PhD
• Phone: +0034 961973536
• Email: mpeiro[@]incliva.es
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Left bundle branch block (LBBB) has been commonly associated with adverse cardiovascular (CV) events, but the effect of an isolated LBBB on maximal functional capacity is not well characterized.

The study's main objective is to evaluate the effect of LBBB on maximum functional capacity.

Description:

Left bundle branch block (LBBB) has been commonly associated with adverse cardiovascular (CV) events, but the effect of an isolated LBBB on maximal functional capacity is not well characterized.

The main objective of the study is to evaluate the effect of LBBB on maximum functional capacity (objectively evaluated by the maximum oxygen consumption -VO2max- at peak exercise in a cardiopulmonary stress test -CPET-) in subjects with LBBB without known cardiovascular disease and compare these data with controls without LBBB.

This is a prospective study that will be carried out in a single centre. All patients with a diagnosis of LBBB and without evidence of structural heart disease in imaging tests will be enrolled. For each candidate with LBBB, one control without LBBB and matched for age, sex, body surface area, and daily physical activity will be selected. All included subjects will undergo a CPET and echocardiography. A sample size estimation [alpha: 0.05, power: 80%, and a clinically significant VO2max difference between groups of at least 10%] of 148 subjects (74 subjects with LBBB + 74 controls) would be necessary to test our hypothesis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 148
• Est. completion date: December 31, 2024
• Est. primary completion date: January 22, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Adult >18 years old

• ECG criteria of left bundle branch block (for controls without left bundle branch block )

• Provide informed consent

Exclusion Criteria:

• Inability to perform a maximal baseline exercise test;

• Structural heart disease, valve heart disease or diastolic dysfunction estimated by two-dimensional echocardiography;

• Previous ischemic heart disease, heart failure, myocardiopathy or myocarditis

• Effort angina during cardiopulmonary exercise testing (CPET);

• Any moderate pulmonary disease;

• Anaemia

• Left ventricular ejection fraction < 55%.

Related Conditions & MeSH terms

• Bundle-Branch Block
• Left Bundle-Branch Block

Intervention

Diagnostic Test:
• Cardiopulmonary exercise testing
Maximal functional capacity will be evaluated using incremental and symptom-limited cardiopulmonary exercise testing (CPET) on a bicycle ergometer, beginning with a workload of 10 W and increasing gradually in a ramp protocol at 10-W increments every 1 minute. We will define maximal functional capacity as when the patient stops pedalling because of symptoms, and the respiratory exchange ratio (RER) is =1.1. During exercise, patients were monitored with 12-lead electrocardiogram and blood pressure measurements every 2 minutes. Gas exchange data and cardiopulmonary variables were averages of values taken every 10 seconds. Peak oxygen consumption (PeakVO2) will be defined as the highest value of oxygen consumption during the last 20 seconds of exercise.
• Echocardioghaphy
Doppler echocardiogram examinations were performed under resting conditions using 2-dimensional echocardiography. Left ventricular end-diastolic volume and left ventricular ejection fraction will be measured according to the European Society of Echocardiography

Locations

Country	Name	City	State
Spain	Marta Peiro	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
Fundación para la Investigación del Hospital Clínico de Valencia

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peak oxygen consumption	Peak oxygen consumption at peak exercise of a maximal symptom-limited cardiopulmonary exercise testing. Units peak oxygen consumption : mL/kg/min	Eligible patients will perform only one cardiopulmonary exercise testing on the first visit. Peak oxygen consumption will be evaluated during the procedure and compared to control patients.
Secondary	Left ventricular end-diastolic volume	Evaluate left ventricular end-diastolic indexed volume by echocardiography at rest. Unit: ml/m2	Eligible patients will perform only one echocardiography on the first visit. Left ventricular end-diastolic volume will be assessed during the procedure and compared to control patients.
Secondary	Left ventricular ejection fraction	Evaluate left ventricular ejection fraction by echocardiography at rest. Unit: %	Eligible patients will perform only one echocardiography on the first visit. Left ventricular ejection fraction will be assessed during the procedure and compared to control patients.